GLP-1 Receptor Agonists for Thin Patients on Multiple Drugs with SC Insulin

Benefits of Adding GLP-1 Receptor Agonists to Insulin Therapy

GLP-1 receptor agonists effectively lower glucose by stimulating insulin secretion and reducing glucagon secretion in a glucose-dependent manner, delaying gastric emptying, and reducing food intake via central appetite suppression 1
The American Diabetes Association recommends that GLP-1 receptor agonists can reduce HbA1c and body weight, unlike the weight gain typically seen with intensification using prandial insulin, when added to basal insulin 2
GLP-1 receptor agonists have high glucose-lowering efficacy with minimal risk of hypoglycemia when used alone, though they may increase hypoglycemic potential when combined with insulin or sulfonylureas, as reported by the American College of Clinical Endocrinologists 3
The combination of basal insulin plus a GLP-1 receptor agonist is associated with weight loss and less hypoglycemia compared to regimens using insulin alone, according to the American College of Physicians 4

In patients who have failed to achieve glycemic targets on basal insulin in combination with oral medications, GLP-1 receptor agonists are a preferred option before advancing to multiple daily insulin injections, as recommended by the American Association of Clinical Endocrinologists 2

Several GLP-1 receptor agonists are available with different dosing frequencies, and evidence suggests that the glucose-lowering effect may be greatest for semaglutide once weekly, followed by dulaglutide and liraglutide, then exenatide once weekly, and finally exenatide twice daily and lixisenatide, as reported by the European Association for the Study of Diabetes 3
The American Society of Health-System Pharmacists recommends starting with a low dose and titrating slowly to minimize gastrointestinal side effects, which are the most common adverse events 5

The most common adverse effects are gastrointestinal symptoms, which typically occur in the initial stage of treatment and gradually diminish over time, according to the International Diabetes Federation 1
Rare but serious adverse effects include acute pancreatitis; GLP-1 receptor agonists should be used with caution in patients with a history of pancreatitis, as warned by the Anaesthesia society 5

Several GLP-1 receptor agonists have demonstrated cardiovascular protective effects in patients with type 2 diabetes with a history of cardiovascular disease or cardiovascular risk factors, as reported by the American College of Cardiology 1
For patients with established atherosclerotic cardiovascular disease, GLP-1 receptor agonists are particularly recommended due to their proven cardiovascular benefits, according to the Journal of the American College of Cardiology 6

Assess the patient's current insulin regimen and glycemic control, then consider adding a GLP-1 receptor agonist to existing insulin therapy, reducing basal insulin dose by approximately 20% if HbA1c ≤8%, as recommended by the Annals of Internal Medicine 4
If transitioning from multiple daily insulin injections to basal insulin plus GLP-1 receptor agonist, maintain basal insulin but reduce dose by 20%, discontinue prandial insulin, and initiate GLP-1 receptor agonist at the lowest dose, as suggested by the American Diabetes Association 4 and the European Association for the Study of Diabetes 2

The combination of GLP-1 receptor agonists and insulin may be particularly beneficial for thin patients who are insulin-deficient but still have some beta-cell function, as GLP-1 receptor agonists enhance glucose-dependent insulin secretion, according to the American Association of Clinical Endocrinologists 3
For patients with significant insulin deficiency, careful monitoring is needed as GLP-1 receptor agonists require some residual beta-cell function for optimal efficacy, as reported by the Diabetes Care journal 7

Evaluate the patient's current glycemic control, including HbA1c levels, to determine if they are suitable candidates for transitioning to GLP-1 receptor agonists, as recommended by the American College of Physicians, based on evidence from the Annals of Internal Medicine 8

Expect weight loss of approximately 2-3 kg over 6 months, which may require further insulin dose adjustments, according to the American Diabetes Association, as reported in Diabetes Care 9